Christine Ryan retweeted
The FARAPULSE™ Pulsed Field Ablation System is now FDA approved! FARAPULSE™ offers tissue selective cardiac #ablation for the treatment of PAF which minimizes thermal risk. See the FARAPULSE™ difference: bostonscientific.com/en-US/p…
Safety info: bit.ly/47VaqXO
Christine Ryan retweeted
TOMORROW at AF Symposium: Join an exciting panel of experts for an in-depth #LAAC discussion on stroke risk management in #AFib. View the details: bit.ly/3ueWuKe
Walid Saliba, MD @Drdevignair @jfreeMD @SDoshiMD @RPHortonMD @omwazni @VivekReddyMD Andrew Farb, MD
Christine Ryan retweeted
The AVANT GUARD clinical trial has commenced and will evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) System as a first-line treatment for persistent atrial fibrillation (AF). Learn more: news.bostonscientific.com/20…
Christine Ryan retweeted
The WATCHMAN FLX™ Pro LAAC Device featuring HEMOCOAT™ Technology takes the next step forward in #LAAC with three first-ever features to advance performance and safety and optimize healing. Learn more ➡ bit.ly/40CdCW1
IFU: bit.ly/40EG7CC
Christine Ryan retweeted
A two year journey, with the FROZEN-AF IDE clinical trial in July 2020 to post approval launch this week. We successfully completed multiple procedures using this system using zero fluoroscopy as we completed the first cases in Arkansas to launch the system since FDA approval. What a journey this has been coming the full circle from the IDE trial to the commercial launch . So proud of our team at Arrhythmia Research Group @StBernards and White River Medical center for living this journey with me . #epeeps @BSCCardiology @WomenAs1 #ArrhythmiaResearchGroup
Christine Ryan retweeted
Just in from #ESCCongress! FARAPULSE™ Pulsed Field Ablation System has met all end points for primary safety and efficacy in the ADVENT Pivotal Trial and been shown to be non-inferior to standard-of-care thermal ablation (RF and Cryo).
Christine Ryan retweeted
Join us for the EU-PORIA Late-Breaking Clinical Trial on May 20 and learn more about real world use of FARAPULSE™ only at #HRS2023. bit.ly/3HEtU8P
Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
Christine Ryan retweeted
Discover how the ADVENT Pivotal Trial will bridge the crucial gap in understanding the impact of FARAPULSE™.
bit.ly/3Vbe4rP
Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
Christine Ryan retweeted
Congratulations to @VivekReddyMD and team on the first procedure of the ADVANTAGE AF trial using the FARAPULSE™ PFA System.
Caution: Investigational Device. Limited by US law to investigational use only. Not available for sale.
Christine Ryan retweeted
View real world clinical & pre-clinical publications and explore the data behind the FARAPULSE™ PFA System here: bit.ly/3Ynl6dJ
Caution: Investigational Device. Limited by US law to investigational use only. Not available for sale.
Christine Ryan retweeted
In the IMPULSE, PEFCAT and PEFCAT II trials, FARAPULSE™ PFA System use reported a durable isolation of 96% of PVs. See the data here: bit.ly/3H7H7ra
Caution: Investigational Device. Limited by US law to investigational use only. Not available for sale.
Christine Ryan retweeted
The WATCHMAN FLX™ #LAAC device demonstrated 90% complete closure* while Amulet™ demonstrated 63% complete closure* in their respective IDE trials. Learn more: bit.ly/3Na3mxu
Safety info: bit.ly/3sGkeCx
Christine Ryan retweeted
Join us for the next Virtual #MedEd Program & peer-to-peer discussion led by @DavidBDeLurgio, @PaulMahoneyMD & @sean_pokorney on the most recent and largest real-world data release by the ACC NCDR #LAAO Registry. Reserve your spot for the June 15 program: bit.ly/3lL7NCg
Christine Ryan retweeted
SURPASS is the largest WATCHMAN FLX study to date with 16,048 patients. The 0.37% safety endpoint confirmed the best-in-class safety profile of WATCHMAN FLX in real-world use. bddy.me/3hsmHey #CRT2022 #CardioTwitter
Christine Ryan retweeted
Evolved from 20 years of WATCHMAN innovation and experience gained from 150,000+ successful implants, WATCHMAN FLX is the #LAAC technology with proven safety and trusted patient outcomes. See the data: bddy.me/3FynBjf
Christine Ryan retweeted
Check out the on-demand session focused on the head-to-head comparison data on device closure, #LAAC clinical data, evidence gaps, and more at #TCT2021. Info: bostonscientific.com/en-US/m…
Christine Ryan retweeted
See the newly published 12-month data from the PINNACLE FLX trial, now available via @CircAHA: bddy.me/2QOWwog
Safety info: bddy.me/32As7fW
Christine Ryan retweeted
Over 150,000 people have left blood thinners behind with WATCHMAN #LAAC, the one-time, minimally invasive procedure that protects your #NVAF patients for life. Learn more at bddy.me/3t8AhZc
Christine Ryan retweeted
WATCHMAN FLX™ #LAAC device expands the treatable patient population, with a 98.8% procedural success rate in the pivotal PINNACLE FLX Trial. Learn more: bddy.me/3fsLTj2
SAFETY INFO: bddy.me/2HseV5N
Christine Ryan retweeted
With nearly 700 WATCHMAN Implants, Dr. Doug Gibson discusses his experience deploying the new WATCHMAN FLX™ #LAAC Device.
Safety info: bddy.me/31m5QCJ
This Post is from an account that no longer exists. Learn more